ARTICLE | Clinical News
Saphris asenapine regulatory update
August 17, 2009 7:00 AM UTC
FDA approved an NDA from Schering-Plough for Saphris asenapine sublingual tablets for the acute treatment of schizophrenia and for acute treatment of manic or mixed episodes associated with bipolar I ...